Skip to content

Aclaris Therapeutics ACRS Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin76.3%-9.7pp73.3%-11.8pp85.6%-4.0pp85.8%-4.8pp86%-3.0pp
Operating margin-961.9%-168pp-975.9%-218pp-973.9%-803pp-873.4%-663pp-793.6%-516pp
Net margin-832.6%-100pp-829.6%-124pp-900%-763pp-802%-619pp-732.4%-484pp
Returns
Return on equity-48.4%+42.6pp-50.2%+34.3pp-113.2%-87.4pp-101.4%-64.0pp-91%-42.6pp
Return on invested capital-69%+55.9pp-69.8%+41.8pp-168.2%-123pp-131.8%-80.9pp-124.9%-54.2pp
Efficiency
Asset turnover-0.1×0.0×0.1×0.0×0.1×-0.1×0.1×-0.1×
Liquidity
Current ratio-1.0×3.4×-0.6×3.9×-3.1×3.9×-3.6×5.1×-1.7×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$1.12-5.3%$0.84-58.2%$0.98-46.3%$1.07-42.7%$1.18-41.1%
Valuation
Market capitalization$685.75M+337%$326.12M+22.9%$205.83M+151%$164.59M+110%$165.47M+88.1%
Price / sales82×+73.1×41.7×+27.5×13.1×+10.0×9.8×+7.4×9.3×+6.5×
Price / book4.8×+3.7×3.2×+1.5×1.7×+1.1×1.2×+0.7×1.1×+0.5×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Aclaris Therapeutics's profit margins?
Aclaris Therapeutics (ACRS) runs a 76.3% gross margin and a -961.9% operating margin, with a -832.6% net margin.
Where do Aclaris Therapeutics's ratios come from?
Every ratio is computed from Aclaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.